Lundbeck begins phase II trial of antibody for migraine prevention

Antibody treatment Lu AG09222 will be tested in a phase II trial including around 230 patients, the company reports. The candidate uses a different mechanism than the relatively new class of CGRP receptors, which have been gaining ground on the migraine market.

Photo: Jens Dresling

A few days after receiving pivotal European approval for its migraine drug Vyepti, Lundbeck is moving ahead with another candidate for the treatment of migraines.

On Monday, the pharmaceutical company reports that preparations have been made for a phase II study to commence with the drug candidate Lu AG09222, which is a treatment for the prevention of migraines like Vyepti.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs